plastic reconstructive surgery News
-
Agreement signed with TELA Bio Inc
Next Science Limited (ASX:NXS) (Next Science) is pleased to announce that it has signed a multi-year distribution agreement with NASDAQ listed medical technology company, TELA Bio, Inc in relation to the supply of a white labelled version of Next Science’s proprietary XPERIENCETM No Rinse Antimicrobial Solution. The new agreement grants TELA Bio, Inc exclusive rights across the US plastic ...
-
Onlume Receives FDA 510(k) Clearance for Fluorescence-guided Surgery Device
OnLume has received 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This ...
By OnLume Inc.
-
Checkpoint Surgical Enrolls First Patient in Nerve Regeneration Clinical Study
Checkpoint Surgical, Inc., the leader in intraoperative nerve repair stimulation technology, today announced it has enrolled the first patient in its multi-center clinical study of the company’s breakthrough nerve regeneration technology. The patient was enrolled at The Ohio State University, one of four sites actively enrolling patients in the double-blind, randomized clinical trial. Other ...
-
BioAesthetics Accelerates Growth with Research Breakthrough and Regional Expansion
BioAesthetics Corporation, a company transforming plastic and reconstructive surgeries through regenerative medicine, closed a financing round led by Silicon Valley-based Hemi Ventures. Investors included San Francisco’s IndieBio, the world’s largest biotech accelerator, the New Orleans BioFund, and the New Orleans Startup Fund. “We’re tremendously excited to join the ...
-
Ankasa Regenerative Therapeutics Receives $8.5 Million in First Tranche of $17 Million Series A Financing Led by Avalon Ventures
Ankasa Regenerative Therapeutics, Inc. (Ankasa), a company focused on pharmaceutical preparations for reactivation of stem cells for organ and tissue regrowth, tissue repair and healing, has received $8.5 million in the first tranche of a $17 million Series A round of financing led by La Jolla-based Avalon Ventures. Other participants in the financing include Heraeus Medical, a global business ...
-
Poietis and Assistance Publique – Hôpitaux de Marseille (AP-HM) annouce the first installation of a 3D bioprinting platform for manufacturing implantable biological tissues in hospitals
The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product (ATMP) manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine. The objective is now to start the first clinical trial of a 3D printed ...
By Poietis
-
FDA approves Sonavex`s EchoSure system
The FDA has granted its seal of approval to Sonavex to begin shipping its EchoSure system to providers across the U.S. A combination of 3D ultrasound imaging and advanced deep learning algorithms, the device automates visual and quantitative analysis to monitor and provide up-to-date information on blood flow following surgical procedures. “Doppler ultrasound is an accurate imaging ...
-
BioAesthetics Announces University Clinical Study for its Nipple Reconstruction Graft
BioAesthetics Corporation today announced a clinical study of its nipple reconstruction graft will be performed at Stanford Medicine beginning in 2021. The BioAesthetics® NACgraft™ biologic matrix is a decellularized skin allograft of the human nipple-areolar complex (NAC) intended to replace the NAC when lost due to mastectomy or other procedure. BioAesthetics hopes the NACgraft will ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you